Skip to content

Join The Lazy Contractor's Blueprint live on Nov 28 — show up and get 1,000 free Mindy creditsJoin The Lazy Contractor's Blueprint, free and live on Nov 28

Register free
Home/Contractors/Melinta Therapeutics, LLC/contracts

Federal Contractor Profile

Melinta Therapeutics, LLC

$65M obligated·7 awards·2 agencies·3 NAICS
OverviewContractsAgenciesNAICS

Federal Contracts

Showing award actions 1–7 of 7 funded award actions, most recent first.

Contracts with positive obligations
7
Funded award actions shown
7
Obligations shown
$65M
Awarding agencies
2

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of September 18, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Sep 25, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00022541714ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN$8.6M
Sep 12, 2025Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00022541714ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN$13M
Sep 5, 2024Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00022541714ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN$4.6M
May 13, 2024Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00022541714ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN$1.0M
Jul 6, 2023Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50123C00022541714ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN$21M
Sep 23, 2016Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201300009C541711CEMPRA - SOLITHROMYCIN (CEM-101) FOR CIVILIAN USE AND BROAD BIOTERROR THREAT MEDICAL COUNTERMEASURES.$8.0M
Feb 23, 2016Department of Health and Human ServicesOFF ASST SEC ADM AND MGMTHHSO100201300009C541711CEMPRA - SOLITHROMYCIN (CEM-101) FOR CIVILIAN USE AND BROAD BIOTERROR THREAT MEDICAL COUNTERMEASURES.$26M

Get Alerted Before Melinta Therapeutics, LLC's Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free